Trials / Completed
CompletedNCT02634307
A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1
A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,057 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 8700 for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS). The secondary objective of this study is to evaluate treatment effect over time in adult participants with RRMS treated with ALKS 8700.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALKS 8700 | Administered as specified in the treatment arm. |
Timeline
- Start date
- 2015-12-10
- Primary completion
- 2021-06-01
- Completion
- 2021-11-11
- First posted
- 2015-12-18
- Last updated
- 2022-07-26
- Results posted
- 2022-06-24
Locations
115 sites across 10 countries: United States, Belgium, Bulgaria, Canada, Germany, Poland, Russia, Serbia, Spain, Ukraine
Source: ClinicalTrials.gov record NCT02634307. Inclusion in this directory is not an endorsement.